Evaluation of the Efficacy of Radiotherapy Concurrent Temozolomide Chemotherapy in Patients with Brain Metastases

应学明,吴浩源,熊建萍,罗宵,张晓华

DOI: https://doi.org/10.3969/j.issn.1001-5930.2006.05.022

2006-01-01

Abstract:Objective To determine the efficacy,tolerability,and safety of concurrent temozolomide chemoradiotherapy in patients with brain metastases.Methods Sixteen patients with brain metastases were treated by radiotherapy alone,including whole brain radiotherapy and stereotatic radiotherapy (group WBI+SRT).Twenty-six patients with brain metastases were treated with the same way,and concurrent temozolomide chemotherapy (group WBI+SRT+TMZ).The entire tow groups patients were received 30～40 Gy conventional fractionated external beam radiotherapy in 3～4 weeks for the whole brain,and then plus X-ray stereotactic radiotherapy for the local tumor.The fractionated dosage of the stereotactic radiotherapy was 5～8 Gy,and three times weekly,and the total dose of the local tumor was 55～72 Gy.The group WBI+SRT+TMZ received concurrent temozolomide chemotherapy when they received irradiation.The schedule of concomitant chemotherapy was temozolomide 100 mg by oral administration on day 1 to 5 weekly.Followed by separation 1 week after the temozolomide was administrated 2 weeks.Followed up 3～25 months.Results The overall response rates (CR+PR) were 93.75% in the group WBI+SRT,including nine (56.25%) patients with complete responses and six (37.5%) partial responses,and 100% in the group WBI+SRT+TMZ,including twenty-one (80.8%) complete responses and five (19.2%) partial responses,but not significant difference (P0.05).The median recurrent period and median survival period in the radiotherapy group alone were 9.8 months and 11.5 months individually,as compared with 12 months and 13.2 months in the group of radiotherapy concurrent temozolomide chemotherapy,and with significant difference (P0.05).Hematologic toxicity of three to four grade in the group radiotherapy alone were two (12.5%) and nine (34.6%) in the group of radiotherapy concurrent temozolomide chemotherapy,and the approaches without statistical significance (P0.05).Conclusion For brain metastases,radiotherapy concurrent temozolomide chemotherapy was safe and efficient,and significant improvement in the median recurrence and survival period.